# US 2026/0216122 A1 · Pharmaceutical composition comprising enavogliflozin and metformin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216122 A1
- Document ID: US20260216122A1
- Status: Published application
- Kind: A1
- Application number: 19/143,621
- Filed: 2023-12-28
- Published: 2026-07-30
- Earliest claimed: 2022-12-30
- Assignees: Daewoong Pharmaceutical Co., Ltd.
- Applicants: Daewoong Pharmaceutical Co., Ltd.
- Inventors: Minhyung Park; On Hwang; Songyi Ha; Gyoungwon Kim; Hoe Sung Kim; Sangeun Cho; Gwan Young Kim
- Web page: https://patentgrep.com/patent/US20260216122A1

## CPC

- A61K 31/351: not condensed with another ring
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 31/155: Amidines ([IMAGE cpc-sch-A61K-1029.gif]), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a pharmaceutical composition comprising enavogliflozin and metformin. The pharmaceutical composition, according to the present invention, makes it possible to implement an excellent preparation that provides the same level of medicinal efficacy as the combination therapy of a single tablet of metformin and a single tablet of enavogliflozin, despite a large content difference between metformin and enavogliflozin.

## Claims

### Claim 1

A pharmaceutical composition in a single dosage form comprising:
a compartment including metformin or a pharmaceutically acceptable salt thereof and a compartment including enavogliflozin or a pharmaceutically acceptable salt thereof, wherein the compartments are formulated in a separated form from each other,
wherein the enavogliflozin compartment is included at 10 to 20 parts by weight with respect to 100 parts by weight of the entire pharmaceutical composition, and
wherein enavogliflozin or a pharmaceutically acceptable salt thereof in the enavogliflozin compartment is included at less than 0.3 parts by weight with respect to a total of 100 parts by weight of the enavogliflozin compartment.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the enavogliflozin compartment comprises enavogliflozin or a pharmaceutically acceptable salt thereof, an excipient, a disintegrant, and a glidant, and the metformin compartment comprises metformin or a pharmaceutically acceptable salt thereof, a binder, a sustained-release agent, and a glidant.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the enavogliflozin compartment comprises an excipient selected from the group consisting of lactose monohydrate; mannitol; a mixture of microcrystalline cellulose and lactose monohydrate; and a mixture of microcrystalline cellulose, mannitol and pregelatinized starch, and the excipient is included at 80 to 85 parts by weight with respect to a total of 100 parts by weight of the enavogliflozin compartment.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein when the enavogliflozin compartment comprises lactose monohydrate as an excipient, the lactose monohydrate is included at 40 to 100 parts by weight with respect to a total of 100 parts by weight of all excipients in the enavogliflozin compartment,
wherein when the enavogliflozin compartment comprises mannitol as an excipient, the mannitol is included at 20 to 100 parts by weight with respect to a total of 100 parts by weight of all excipients in the enavogliflozin compartment,
wherein when the enavogliflozin compartment comprises microcrystalline cellulose as an excipient, the microcrystalline cellulose is included at less than 65 parts by weight with respect to a total of 100 parts by weight of all excipients in the enavogliflozin compartment, or
wherein when the enavogliflozin compartment comprises pregelatinized starch as an excipient, the pregelatinized starch is included at 5 to 40 parts by weight with respect to a total of 100 parts by weight of all excipients in the enavogliflozin compartment.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein, when the enavogliflozin compartment comprises microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, the mannitol is included at 20 to 65 parts by weight with respect to a total of 100 parts by weight of all excipients in the enavogliflozin compartment.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein, when the enavogliflozin compartment comprises microcrystalline cellulose, mannitol, and pregelatinized starch as excipients, the microcrystalline cellulose, mannitol and pregelatinized starch are included at a weight ratio of 1:0.5 to 2:0.15 to 1.5 in the enavogliflozin compartment.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the enavogliflozin compartment comprises a disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate, crospovidone, and low-substituted hydroxypropyl cellulose, and the disintegrant is included at 5 to 20 parts by weight with respect to a total of 100 parts by weight of the enavogliflozin compartment.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the enavogliflozin compartment comprises one or more of light anhydrous silicic acid and talc as a glidant, and the glidant is included at 1.5 to 3 parts by weight with respect to a total of 100 parts by weight of the enavogliflozin compartment.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the metformin compartment comprises carboxymethylcellulose sodium, povidone, or a mixture thereof as a binder, and the binder is included at 2 to 5 parts by weight with respect to a total of 100 parts by weight of the metformin compartment.

### Claim 13 (depends on 1)

The pharmaceutical composition of claim 1, wherein the metformin compartment comprises one or more of hydroxypropyl methylcellulose and oxidized polyethylene as a sustained-release agent, and the sustained-release agent is included at 15 to 40 parts by weight with respect to a total of 100 parts by weight of the metformin compartment.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the metformin compartment comprises magnesium stearate as a glidant at 0.5 to 1 part by weight with respect to a total of 100 parts by weight of the metformin compartment.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dissolution rate of the enavogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution solution after 10 minutes is 80% or more with respect to the total content of the enavogliflozin or a pharmaceutically acceptable salt thereof, or
wherein the dissolution rate of the enavogliflozin or a pharmaceutically acceptable salt thereof in a pH 1.2 dissolution solution after 45 minutes is 85% or more with respect to the total content of the enavogliflozin or a pharmaceutically acceptable salt thereof.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dissolution rate of the metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution solution after 1 hour is 20% or more with respect to the total content of the metformin or a pharmaceutically acceptable salt thereof,
wherein the dissolution rate of the metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution solution after 3 hours is 45% or more with respect to the total content of the metformin or a pharmaceutically acceptable salt thereof, or
wherein the dissolution rate of the metformin or a pharmaceutically acceptable salt thereof in a pH 6.8 dissolution solution after 12 hours is 85% or more with respect to the total content of the metformin or a pharmaceutically acceptable salt thereof.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the enavogliflozin compartment comprises a granulate in which pre-mixed granules including enavogliflozin or a pharmaceutically acceptable salt thereof are mixed with a post-mixed part, and the granulate is a dry granulate.

### Claim 21 (depends on 20)

The pharmaceutical composition of claim 20, wherein the pre-mixed granules comprise enavogliflozin or a pharmaceutically acceptable salt thereof, an excipient, and a glidant.

### Claim 22 (depends on 20)

The pharmaceutical composition of claim 20, wherein the post-mixed part comprises an excipient, a disintegrant, and a glidant.

### Claim 23 (depends on 20)

The pharmaceutical composition of claim 20, wherein each of the pre-mixed granules and the post-mixed part comprise one or more excipients, and wherein the weight ratio of the excipient in the pre-mixed granules and the excipient in the post-mixed part ranges from 1:1 to 1:4.

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the metformin compartment comprises a granulate in which pre-mixed granules including metformin or a pharmaceutically acceptable salt thereof are mixed with a post-mixed part, and the granulate is a wet granulate.

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a bilayer tablet.

### Claim 30 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises enavogliflozin at a dose of 0.1 to 0.5 mg, and metformin at a dose of 500 to 1,000 mg.

### Claim 31

(canceled)
